The "Overview: Research Status and Progress of Monkeypox Vaccine" recently released by the Chinese Center for Disease Control and Prevention Weekly revealed that China's self-developed monkeypox mRNA (messenger ribonucleic acid) vaccine is about to enter clinical trials.
Since 2022, there have been outbreaks of monkeypox in many countries around the world. The high-risk groups for monkeypox virus infection are mainly immunocompromised people, such as AIDS patients without **. Vaccination is the most effective means of preventing monkeypox. Currently, there is no approved vaccine for monkeypox worldwide, and prevention of monkeypox still relies on smallpox vaccination. However, there are certain safety concerns about the smallpox vaccine, and there is an urgent need for a safer, more effective and highly specific monkeypox vaccine in response to the current monkeypox outbreak.
According to the China Disease Control and Prevention, China's research and development of monkeypox vaccine is progressing rapidly, and the self-developed monkeypox mRNA (messenger ribonucleic acid) vaccine is about to enter clinical trials. The R&D team of China Biotech Vaccine has developed and tested three kinds of monkeypox mRNA vaccines, which can strongly induce anti-poxvirus-specific antibodies on immunized mice, which are safer than existing live attenuated virus vaccines, and can produce neutralizing antibodies to prevent viruses earlier after immunization. The R&D team of the Seventh Affiliated Hospital of Sun Yat-sen University has developed a multivalent monkeypox mRNA vaccine, which has been confirmed by a variety of indicators to be effective and safe.
Countries are also stepping up the development of a new generation of monkeypox vaccines to further improve the safety and protection of the vaccine, reduce the pathogenicity and transmission of the monkeypox virus, and the new generation of monkeypox vaccines is expected to be more suitable for people with immunodeficiency, ** disease or cardiovascular diseases. According to the Guidelines for Public Protection against Monkeypox (2023) issued by the National Center for Infectious Diseases and the Chinese Preventive Medicine Association, monkeypox vaccination is not recommended for the general population at present, and high-risk groups infected with monkeypox virus must strengthen health education and implement monkeypox vaccination programs.
*: Beijing**client reporter Wang Yaoqi Chai Rong.
Process edit: u027